Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
19.33
-0.50 (-2.52%)
Aug 24, 2026, 10:33 AM EDT - Market open
Avalo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.06 | 0.06 | 0.44 | 1.92 | 18.05 | 5.4 | |
Revenue Growth | -86.62% | -86.62% | -77.08% | -89.34% | 234.40% | -19.42% |
Cost of Revenue | 47.95 | 35.35 | 15.28 | 9.95 | 25.99 | 50.12 |
Gross Profit | -47.89 | -35.29 | -14.84 | -8.02 | -7.94 | -44.72 |
Selling, General & Admin | 27.06 | 22.9 | 17.24 | 10.3 | 13.91 | 24.66 |
Research & Development | 16.4 | 14.74 | 8.8 | 5.12 | 8.05 | 11.21 |
Amortization of Goodwill & Intangibles | - | - | - | - | 0.04 | 1.55 |
Operating Expenses | 43.47 | 37.64 | 26.04 | 15.42 | 22 | 37.41 |
Operating Income | -91.36 | -72.93 | -40.87 | -23.44 | -29.94 | -82.13 |
Interest Expense | - | - | - | -3.42 | -4.17 | -2.39 |
Interest & Investment Income | 5.67 | 4.35 | 3.31 | - | - | - |
Other Non Operating Income (Expenses) | -14.47 | -9.52 | 30.19 | -0.76 | -0.02 | -0.02 |
EBT Excluding Unusual Items | -100.16 | -78.09 | -7.37 | -27.62 | -34.13 | -84.55 |
Merger & Restructuring Charges | - | - | - | - | -7.5 | - |
Impairment of Goodwill | - | - | - | -3.91 | - | - |
Pretax Income | -100.16 | -78.09 | -35.02 | -31.53 | -41.63 | -84.55 |
Income Tax Expense | 0.17 | 0.17 | 0.11 | 0.01 | 0.03 | -0.2 |
Earnings From Continuing Operations | -100.33 | -78.26 | -35.13 | -31.54 | -41.66 | -84.35 |
Earnings From Discontinued Operations | - | - | - | - | - | -0.03 |
Net Income | -100.33 | -78.26 | -35.13 | -31.54 | -41.66 | -84.38 |
Net Income to Common | -100.33 | -78.26 | -35.13 | -31.54 | -41.66 | -84.38 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 24 | 13 | 4 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 24 | 13 | 7 | 0 | 0 | 0 |
Shares Change | 158.89% | 78.82% | 2599.19% | 608.45% | 8.32% | 41.86% |
EPS (Basic) | -4.18 | -5.84 | -7.94 | -113.58 | -1062.65 | -2331.41 |
EPS (Diluted) | -4.18 | -5.84 | -20.91 | -113.58 | -1062.65 | -2331.41 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -68.29 | -51.46 | -49.06 | -30.84 | -26.85 | -71.01 |
Free Cash Flow Per Share | -2.84 | -3.84 | -6.54 | -111.04 | -684.81 | -1961.95 |
Gross Margin | - | - | - | - | -43.98% | - |
Operating Margin | -154847.46% | -123601.69% | -9267.80% | -1218.50% | -165.86% | -1521.56% |
Profit Margin | -170055.93% | -132642.37% | -7965.76% | -1639.50% | -230.78% | -1563.10% |
Free Cash Flow Margin | -115745.76% | -87216.95% | -11123.81% | -1602.81% | -148.72% | -1315.39% |
EBITDA | -91.25 | -72.58 | -40.7 | -23.29 | -29.77 | -80.48 |
EBITDA Margin | - | - | - | - | -164.94% | - |
D&A For EBITDA | 0.11 | 0.34 | 0.17 | 0.16 | 0.17 | 1.66 |
EBIT | -91.36 | -72.93 | -40.87 | -23.44 | -29.94 | -82.13 |
EBIT Margin | - | - | - | - | -165.86% | - |
Revenue as Reported | 0.06 | 0.06 | 0.44 | 1.92 | 18.05 | 5.4 |